Australian biotech market watch 22/01/10
Friday, 22 January, 2010
Health and biotech stocks have followed the All Ordinaries on a slide in morning trading on the back of a weak week in Wall St and concerns over the global economy. The All Ords are down 1.8% in early afternoon trading, with the S&P Health Care index experiencing a slight recovery from this morning, down only 0.25% as of 1pm.
One of the biggest drops was had by Mesoblast (ASX:MSB), which shed 18c to $1.95, although it's still up 44% over the past month.
Sirtex Medical (ASX:SRX) has also dropped 6%, down to $7.07, and Prima BioMed is back to 17c after bumping to 18c at yesterday's close.
pSivida (ASX:PVA) shed 23c, down to $4.05, and Patrys (ASX:PAB) has continued its decline of the past week, down 3.9% to 12.5c.
It wasn't all bad news, though. Cochlear (ASX:COH) managed to put on $1.69, to $66.12, in a strong morning's trading.
Xenotransplantation specialists, Living Cell Technology, has had some ups and downs over the past week, but recovered today to the tune of 2.4%, up to 21c.
CSL (ASX:CSL) was up slightly, adding 8c to $31.15, and ResMed (ASX:RMD) was steady.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...